drugset / Trial / NCT00285428
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Timeline
- Start
- 2004-09
- Primary completion
- 2007-10
- Completion
- 2007-10
Publications
- Background Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. doi: 10.3109/10428191003672123.
- Results Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. doi: 10.1200/JCO.2008.19.9117. Epub 2009 May 18.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | veltuzumab | Monoclonal antibody | 80 mg/m2 | Intravenous |
| Subject | veltuzumab | Monoclonal antibody | 120 mg/m2 | Intravenous |
| Subject | veltuzumab | Monoclonal antibody | 200 mg/m2 | Intravenous |
| Subject | veltuzumab | Monoclonal antibody | 375 mg/m2 | Intravenous |